Clinical Trials Logo

Clinical Trial Summary

This observational study aims to look at the connections between kidney stones, insulin resistance, and inflammation. The researchers hypothesize that people who form calcium kidney stones and have insulin resistance may have higher levels of inflammation because they have more visceral fat (fat around the abdominal organs). The study will recruit 20 people who have had calcium kidney stones but don't have diabetes, and 20 healthy people who haven't had kidney stones. All the participants will come to the research center at the University of Chicago Medicine. Participants will have a dual-energy X-ray absorptiometry (DEXA) scan to measure their visceral fat, and give blood and urine samples. The blood will be tested for insulin resistance, inflammatory markers, and other metabolic factors. The urine will be analyzed for substances that increase kidney stone risk. The main goal is to see if the kidney stone formers with insulin resistance have more visceral fat compared to those without insulin resistance and the healthy participants. The researchers will also compare inflammatory marker levels between groups, and look at how visceral fat, inflammatory markers, insulin resistance, and urine stone risk factors are related. The findings may help explain how kidney stones are connected to metabolic conditions like diabetes and cardiovascular disease. Researchers hope this information will help identify stone formers at risk early and develop preventive treatments in the future.


Clinical Trial Description

Participants will be recruited from the University of Chicago Medicine Kidney Stone Clinic (stone formers) and research participant registries (controls). After providing informed consent, participants will complete the following procedures: Pre-Study: 1. One week prior, participants will discontinue vitamin C, multivitamins, calcium supplements, and diuretics. 2. One day prior, participants will complete a 24-hour urine collection and food frequency questionnaire at home. Study Visit: 2. Participants will be admitted to the University of Chicago's Clinical Research Center (CRC) in a fasted state. 3. Three timed (45 minute) urine and blood specimen collections will occur. 4. Three seated blood pressure measurements will be taken. 5. Anthropometric measurements including height, weight, waist and neck circumference will be obtained. 6. A dual-energy X-ray absorptiometry (DEXA) scan will be performed to measure visceral fat content and bone density. 7. A brief clinical history will be obtained, including data on kidney stone episodes, procedures, and current stone burden. 8. Participants will remain fasted until all biological samples have been collected. Water intake will be allowed ad libitum. Sample Analysis: Urine: 1.24-hour and timed urine samples will be analyzed for kidney stone risk chemistries including volume, pH, solutes (calcium, oxalate, uric acid, citrate, etc). 2. Urine supersaturations for calcium oxalate, calcium phosphate, and uric acid will be calculated using EQUIL2 software. 3. Urine albumin and creatinine will be measured. 4. Remaining urine will be stored at -80°C for potential future assays. Blood: 1. Serum glucose will be measured at the CRC laboratory. 2. Serum insulin, C-peptide, glucagon, GLP-1, and inflammatory markers (high-sensitivity CRP [C-reactive protein], IL-6, MMPs [matrix metalloproteinases], TNF-alpha, endotrophin) will be measured at the Diabetes Research and Training Center at the University of Chicago. 3. Other serum chemistries (electrolytes, calcium, creatinine, HbA1c, lipids) will be measured at the clinical laboratory. 4. Remaining serum will be stored at -80°C. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06436235
Study type Observational
Source University of Chicago
Contact Megan Prochaska, MD
Phone 773-702-1000
Email mprocha2@medicine.bsd.uchicago.edu
Status Not yet recruiting
Phase
Start date May 31, 2024
Completion date August 1, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04495699 - Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
Recruiting NCT04559321 - Holmium Vs Trilogy Kidney Stones GUY's 1-2 Phase 3
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Withdrawn NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Not yet recruiting NCT05022537 - Clinical Outcomes of Percutaneous Nephrolithotomy Following Retrograde Percutaneous Nephrostomy Access Using Novel Device in Comparison to Antegrade Access N/A
Completed NCT03872843 - Opioid Free Management After Ureteroscopy Phase 4
Recruiting NCT06412822 - Neutrophil Extracellular Traps (NET's) in Prevalent Kidney Stone
Active, not recruiting NCT06437379 - Infection Control Measures for Patients Undergoing Percutaneous Nephrolithotomy N/A
Recruiting NCT04997668 - Clinical Outcomes and Healthcare Economics of SOLTIVE Compared to Ho:YAG Laser in Urolithiasis N/A
Active, not recruiting NCT04333745 - Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers N/A
Recruiting NCT05701098 - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD) N/A
Recruiting NCT04389853 - Mini-PNCL vs fURS in Management of Nephrolithiasis N/A
Recruiting NCT05334979 - Oxalate and Citrate N/A
Recruiting NCT05591716 - Evaluation of the Efficacy and Safety of Unimodal Bilateral Flexible Ureteroscopy. N/A
Recruiting NCT06209931 - RIRS With Tip Flexible Pressure-controlling Ureteral Access Sheath Versus Mini PCNLfor Kidney Stones
Withdrawn NCT04545528 - The Impact of Nutritional Service in the Stone Clinic on the Patient Urine Collection Results
Completed NCT05714423 - Outcomes in Lower Pole Kidney Stone Management Using Mini-PCNL Compared With Retrograde Intra Renal Surgery N/A
Recruiting NCT03281928 - Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling N/A
Recruiting NCT04835922 - Comparison of Efficacy of Intercostal Nerve Block vs Peritract Infiltration With 0.25% Bupivacaine in PCNL N/A
Recruiting NCT03257306 - Magnetic Ureteral Stent Symptoms - a Comparison to Standard Ureteral Stent as Perceived By the Patient (MAGUSS) N/A